SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Condition(s):Non Small Cell Lung Cancer; Solid TumorLast Updated:February 16, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Non Small Cell Lung Cancer; Solid TumorLast Updated:February 16, 2024Recruiting
Condition(s):Biliary Tract CancerLast Updated:March 21, 2024Recruiting
Condition(s):Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IIIA Colon Cancer; Stage IIIA Rectal Cancer; Stage IIIB Colon Cancer; Stage IIIB Rectal Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal CancerLast Updated:March 2, 2015Completed
Condition(s):Advanced AngiosarcomaLast Updated:May 12, 2020Completed
Condition(s):Neoplasms; Breast NeoplasmsLast Updated:March 5, 2024Active, not recruiting
Condition(s):Kidney CancerLast Updated:June 6, 2022Completed
Condition(s):Non-small Cell Lung CancerLast Updated:January 26, 2010Terminated
Condition(s):Advanced Colorectal CancerLast Updated:December 4, 2023Completed
Condition(s):Soft Tissue SarcomaLast Updated:November 19, 2019Terminated
Condition(s):Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Esophageal Cancer; Nasopharyngeal Cancer; Ovarian Cancer; Solid TumorsLast Updated:July 15, 2020Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.